{"id":70032,"date":"2026-07-15T12:53:33","date_gmt":"2026-07-15T04:53:33","guid":{"rendered":"https:\/\/flcube.com\/?p=70032"},"modified":"2026-07-15T12:53:34","modified_gmt":"2026-07-15T04:53:34","slug":"innovent-biologics-secures-1-1b-global-cd40l-antibody-deal-with-spero-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70032","title":{"rendered":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Innovent Biologics (<a href=\"https:\/\/www.google.com\/finance\/quote\/1801:HKG\">HKG: 1801<\/a>)<\/strong> announced an <strong>exclusive license agreement<\/strong> with <strong>Spero Therapeutics, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/SPRO:NASDAQ\">NASDAQ: SPRO<\/a>)<\/strong> for <strong>IBI355 (SP001)<\/strong>, a <strong>third-generation anti-CD40L monoclonal antibody<\/strong>, in a transaction valued at <strong>approximately USD 1.1 billion<\/strong>. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>Innovent Biologics (HKG: 1801) + Spero Therapeutics (NASDAQ: SPRO)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>IBI355 (SP001) &#8211; third-generation anti-CD40L monoclonal antibody<\/td><\/tr><tr><td><strong>Territory Split<\/strong><\/td><td>Spero: Global excluding Greater China; Innovent: Greater China (Mainland China, HK, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>Approximately USD 1.1 billion<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Upfront payment + development\/regulatory\/sales milestones + tiered royalties<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technical-innovation\" class=\"wp-block-heading\">Drug Profile &amp; Technical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Third-generation, humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks upstream immune activation signal involved in B cells, antigen-presenting cells, and platelets<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Addresses platelet activation issues associated with previous anti-CD40L antibodies while maintaining FcRn interaction for IgG-like half-life<\/li>\n\n\n\n<li><strong>Therapeutic Approach:<\/strong> Non-B-cell-depleting targeted treatment for immune-mediated diseases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-strategy-dual-indication-focus\" class=\"wp-block-heading\">Clinical Development Strategy \u2013 Dual-Indication Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Indication<\/th><th>Timeline<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Spero Therapeutics<\/strong><\/td><td>IgG4-related disease (IgG4-RD)<\/td><td>Q2 2027<\/td><td>Phase II initiation planned<\/td><\/tr><tr><td><strong>Innovent Biologics<\/strong><\/td><td>Sj\u00f6gren&#8217;s disease (SjD)<\/td><td>Early 2027<\/td><td>Phase II initiation planned<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Immune-mediated diseases with chronic inflammation and tissue damage<\/td><td>2027+<\/td><td>Multiple potential indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The dual development strategy leverages each company&#8217;s regional expertise while addressing significant unmet needs in rare autoimmune conditions with limited treatment options.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-differentiation\" class=\"wp-block-heading\">Market Impact &amp; Competitive Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CD40L Target Opportunity:<\/strong> Represents a high-value target in immune-mediated diseases with potential to address multiple indications beyond current B-cell depleting therapies<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Third-generation design specifically addresses historical safety concerns (platelet activation) that halted previous anti-CD40L programs<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> Innovent monetizes global potential while retaining valuable Greater China rights in rapidly growing autoimmune disease market<\/li>\n\n\n\n<li><strong>Financial Upside:<\/strong> $1.1B deal value plus tiered royalties creates substantial revenue potential from a single asset across multiple indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the license agreement and clinical development of IBI355. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[910,198,4813,24,4812],"class_list":["post-70032","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1801","tag-innovent-biologics","tag-nasdaq-spro","tag-rare-orphan-disease-drugs","tag-spero-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70032\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70032\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-15T04:53:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-15T04:53:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics\",\"datePublished\":\"2026-07-15T04:53:33+00:00\",\"dateModified\":\"2026-07-15T04:53:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1801\",\"Innovent Biologics\",\"NASDAQ: SPRO\",\"Rare \\\/ orphan disease drugs\",\"Spero Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70032#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70032\",\"name\":\"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-15T04:53:33+00:00\",\"dateModified\":\"2026-07-15T04:53:34+00:00\",\"description\":\"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70032\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70032#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics - Insight, China&#039;s Pharmaceutical Industry","description":"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70032","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics","og_description":"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.","og_url":"https:\/\/flcube.com\/?p=70032","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-15T04:53:33+00:00","article_modified_time":"2026-07-15T04:53:34+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70032#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70032"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics","datePublished":"2026-07-15T04:53:33+00:00","dateModified":"2026-07-15T04:53:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70032"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1801","Innovent Biologics","NASDAQ: SPRO","Rare \/ orphan disease drugs","Spero Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70032#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70032","url":"https:\/\/flcube.com\/?p=70032","name":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-15T04:53:33+00:00","dateModified":"2026-07-15T04:53:34+00:00","description":"Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO) for IBI355 (SP001), a third-generation anti-CD40L monoclonal antibody, in a transaction valued at approximately USD 1.1 billion. The deal grants Spero exclusive global development and commercialization rights outside Greater China while Innovent retains full rights within its home market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70032#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70032"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70032#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70032"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70032\/revisions"}],"predecessor-version":[{"id":70033,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70032\/revisions\/70033"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}